Document Detail


Lamotrigine (Lamictal IR) for the treatment of bipolar disorder.
MedLine Citation:
PMID:  23140205     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Over the past decade the use of lamotrigine in bipolar disorder has increased. However, the evidence base suggests a more limited role for lamotrigine as part of an overall treatment regimen in bipolar disorder.
AREAS COVERED: We reviewed publications of randomized clinical trials of lamotrigine, emphasizing studies in bipolar disorder. The low burden of adverse effects with lamotrigine has been confirmed in these studies. Its lack of benefit in acute mania is established. Despite modest benefits for a subset of depressive episodes in bipolar disorder, it was not superior to placebo in well-designed studies. As monotherapy, in randomized, blinded trials in rapid cycling bipolar disorder it was not superior to placebo. Its role in maintenance treatment is relatively well established as one component of combination therapy, with evidence for benefits when combined with lithium or valproate. Combination regimens including lamotrigine appear to be superior to monotherapy. Monotherapy utilization of lamotrigine for maintenance treatment is not supported by these studies.
EXPERT OPINION: Lamotrigine has benefits in bipolar disorder management principally as a component of combination treatment which includes a mood stabilizer. The utility of lamotrigine in acute bipolar depression and major depressive disorder is modest.
Authors:
Charles L Bowden; Vivek Singh
Related Documents :
23769995 - Models of autism spectrum disorders: current standards and new developments.
24264285 - The spiritual dynamics of chronic post traumatic stress disorder.
24035645 - Pharmacological treatment of comorbid ptsd and substance use disorder: recent progress.
23884075 - Blast-related traumatic brain injury.
16295475 - Factor x deficiency--a rare disorder.
22361385 - Resistance mechanisms of mycobacterium tuberculosis against phagosomal copper overload.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  13     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-12     Completed Date:  2013-04-18     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2565-71     Citation Subset:  IM    
Affiliation:
The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. bowdenc@uthscsa.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antimanic Agents / therapeutic use*
Bipolar Disorder / drug therapy*
Humans
Treatment Outcome
Triazines / therapeutic use*
Chemical
Reg. No./Substance:
0/Antimanic Agents; 0/Triazines; U3H27498KS/lamotrigine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Osteoporosis healthcare disparities in postmenopausal women.
Next Document:  Antioxidant and phytochemical properties of Carpobrotus edulis (L.) bolus leaf used for the manageme...